CADD-engineered peptide protacs efficiently target PCSK9 for hypercholesterolemia in vivo. Fan G, Guo W, Lu J, He Y, et al. Metabolism 2025 Dec 23:156485. doi: 10.1016/j.metabol.2025.156485.

Read + Share

Amedeo Smart

Independent Medical Education

Fan G, Guo W, Lu J, He Y, et al. CADD-engineered peptide protacs efficiently target PCSK9 for hypercholesterolemia in vivo. Metabolism 2025 Dec 23:156485. doi: 10.1016/j.metabol.2025.156485.
PMID: 41448485